Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 12, 2024

Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, outlines the most significant unaddressed challenges in treating and managing non-small cell lung cancer as the field approaches the American Society of Clinical Oncology's 2024 annual meeting.

Episodes in this series

This series features 1 KOL.

EP. 1 Expert Insights on NSCLC: Unmet Needs and Innovations from ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 2 ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC

Jason Porter, MD, an expert on lung cancer

EP. 3 Evaluating Amivantamab and Lazertinib: Key Findings from the CHRYSALIS-2 Study at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 4 Insights from the TROPION-Lung05 Trial at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 5 Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Jason Porter, MD, an expert on lung cancer

EP. 6 ASCO 2024 and Beyond: Addressing NSCLC Unmet Needs and Future Research Directions

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Richard Bogan, MD

Orexin Agonist Shows Promise for Treating Narcolepsy, Hypersomnia: Richard Bogan, MD

ByPearl Steinzor,Isabella Ciccone, MPH,Richard Bogan, MD

June 17th 2026

Dr Irina Murakhovskaya | Image Credit: Montefiore Einstein

Nipocalimab Offers Rapid Response, Favorable Safety in wAIHA: Irina Murakhovskaya, MD

ByBrooke McCormick,Irina Murakhovskaya, MD

June 17th 2026

Tarik Asselah, MD, PhD, screenshot on AJMC branded Q&A background

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

ByLaura Joszt, MA,Tarik Asselah, MD, PhD

June 16th 2026

ChronicLL | Image Credit: © Saiful52-stock.adobe.com

Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

ByMaggie L. Shaw

June 16th 2026

United Therapeutics plans to seek FDA approval for inhaled treprostinil after phase 3 TETON trials demonstrated improved preservation of lung function in IPF. | Image credit: Peakstock_AdobeStock.jpeg

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

BySabrina McCrear

June 16th 2026

Trending on AJMC

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol

Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer

When Politics Fails Public Health, Communities Pay the Price